Involving Transferase Patents (Class 435/15)
-
Publication number: 20130121983Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: ApplicationFiled: September 5, 2012Publication date: May 16, 2013Applicant: Intrexon CorporationInventors: Timothy David JONES, Francis Joseph Carr
-
Publication number: 20130123260Abstract: The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of rhinovirus infection, methods of treating or preventing rhinovirus infection employing said compounds or pharmaceutical composition comprising the same. The disclosure also relates to compounds of formula (I) for use in the treatment or prophylaxis of exacerbation of respiratory disorders (such as asthma, COPD, bronchitis and/or cystic fibrosis) by rhinovirus infection.Type: ApplicationFiled: June 17, 2011Publication date: May 16, 2013Applicant: RESPIVERT LIMITEDInventors: Catherine Elisabeth Charron, Kazuhiro Ito, William Garth Rapeport
-
Publication number: 20130121989Abstract: Polypeptides with tubulin acetyltransferase activity are described, as are nucleic acids encoding said polypeptides, and methods of use. The invention further provides enhancers and inhibitors of tubulin acetyltransferase activity, as well as cells having altered tubulin transferase activity.Type: ApplicationFiled: October 17, 2012Publication date: May 16, 2013Applicant: University of Georgia Research Foundation, Inc.Inventor: University of Georgia Research Foundation, Inc.
-
Patent number: 8440421Abstract: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process to instigate beneficial human cardiac hypertrophy or for post myocardial infraction (MI) remodeling comprising illiciting an overexpression of ILK, is described. The ILK signaling pathway is also used as a means for cardiac stem cell proliferation and self-renewal.Type: GrantFiled: March 2, 2012Date of Patent: May 14, 2013Inventors: John G. Coles, Gregory Hannigan, Huanzhang Lu
-
Patent number: 8440435Abstract: The present application provides a method of reducing and/or removing diglyceride from an edible oil, comprising admixing an edible oil with an acyl acceptor substrate and a diglyceride:glycerol acyltransferase, wherein the diglyceride:glycerol acyltransferase is characterized as an enzyme which in an edible oil is capable of transferring an acyl group from a diglyceride to glycerol. The diglyceride:glycerol acyltransferase can comprise the amino acid sequence motif GDSX. The present invention also relates to the use of a diglyceride:glycerol acyltransferase in the manufacture of an edible oil, for reducing and/or removing diglyceride from said edible oil and to the use of said enzyme in the manufacture of a foodstuff comprising an edible oil for improving the crystallization properties of said foodstuff.Type: GrantFiled: June 25, 2009Date of Patent: May 14, 2013Assignee: DuPont Nutrition Biosciences ApSInventors: Paul Wassell, Jørn Borch Søe, Jørn Dalgaard Mikkelsen, Anna Cecilie Jentoft Kristensen
-
Publication number: 20130115618Abstract: In general, the present invention provides prognostic and predictive methods and kits for determining the lipogenicity of a tumor in a subject, by making use of phospholipid profiling, whereby a relative increase in mono-unsaturated phospholipid species in combination with a relative decrease in poly-unsaturated phospholipid species is indicative for a more resistant and aggressive lipogenic cancer phenotype.Type: ApplicationFiled: February 10, 2011Publication date: May 9, 2013Applicant: KATHOLIEKE UNIVERSITEIT LEUVENInventor: Johan Swinnen
-
Patent number: 8431355Abstract: The present invention relates to the use of the assessment of the binding between—antibodies elicited against a first glycoprotein, and—at least one glycoform of a second glycoprotein, said second glycoprotein being itself a glycoform of the first protein, wherein said glycoform of the second glycoprotein is selected from a group of glycoforms of the second glycoprotein, each glycoform of said group corresponding to a determined glycosylation state defined by a determined sialylation state, and/or a determined branching state, and/or a determined fucosylation state, provided that said glycosylation state is not uniquely defined by a substantially unsialylated state, for the screening of glycoform specific antibodies directed against a given glycoform of the second glycoprotein.Type: GrantFiled: February 4, 2005Date of Patent: April 30, 2013Assignee: Universite de Provence Aix-Marseille 1Inventors: Catherine Ronin, Sandrine Donadio
-
Patent number: 8431379Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius and variations thereof are provided. Further provided are methods of at least partially degrading xylotriose, xylobiose, and/or arabinofuranose-substituted xylan using isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius and variations thereof.Type: GrantFiled: June 15, 2010Date of Patent: April 30, 2013Assignee: Battelle Energy Alliance, LLCInventors: David N. Thompson, Vicki S. Thompson, Kastli D. Schaller, William A. Apel, David W. Reed, Jeffrey A. Lacey
-
Patent number: 8426418Abstract: Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.Type: GrantFiled: August 26, 2011Date of Patent: April 23, 2013Assignee: CollabRx Inc.Inventors: Robert Coopersmith, Raphael Lehrer
-
Patent number: 8420341Abstract: This invention relates to assays for detecting and measuring ADP. In particular, this invention provides homogeneous luminescent assays that detect ADP generation and measures ADP accumulation based on enzymatic coupling reactions. The assays of the present invention can be applied to all types of kinases and other ADP-generating enzymes, are antibody free, beads free, radioisotope free, and compatible with commonly used kinase buffers.Type: GrantFiled: November 12, 2008Date of Patent: April 16, 2013Assignee: Genewiz Inc., SuzhouInventors: Zhong-Ping Sun, Shihong Li, Conrad Leung, Guo-Juan Liao
-
Patent number: 8420355Abstract: The present invention relates to 4S-iota-carrageenan sulfatase and to the use thereof for partially or totally converting the iota-carrageenan into iota-/alpha-carrageenan or alpha-carrageenan. The invention also relates to the method for extracting said enzyme from a Pseudoalteromonas bacteria population or from red marine algae. Finally, the present invention relates to the use of 4S-iota-carrageenan sulfatase to prepare a texturizing agent containing alpha-carrageenan.Type: GrantFiled: April 22, 2010Date of Patent: April 16, 2013Assignees: Centre National de la Recherche (CNRS), Universite Pierre et Marie Curie (Paris 6)Inventors: Sabine Joncour Genicot, William Helbert
-
Publication number: 20130089880Abstract: Chemiluminescent detection of metabolic by-products of inosine and hypoxanthine to diagnose ischemic events such as early acute cardiac ischemia.Type: ApplicationFiled: November 29, 2012Publication date: April 11, 2013Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventor: Virginia Commonwealth University
-
Publication number: 20130089882Abstract: In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.Type: ApplicationFiled: November 7, 2012Publication date: April 11, 2013Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: UNIVERSITY OF SOUTH CAROLINA
-
Patent number: 8409821Abstract: A method of assessing arachidonic acid (AA) metabolites-dependent hypertension by measuring glucuronidated dihydroxyeicosatrienoic acids (DHETs) and DHET metabolites in a biological sample which contains the epitopes unique to DHET (using any methods including GC/MS, LC/MS or ELISA). An example of the glucuronidated DHET metabolite is DHET-alcohols such as omega or omega-1 oxidated DHET and DHET esterified glycerol. The method further includes determining the amount of glucuronidated molecules containing a DHET-specific epitope which is immunoreactive with antibodies produced against DHETs.Type: GrantFiled: March 3, 2010Date of Patent: April 2, 2013Assignee: Detroit R&DInventors: Hyesook Kim, Jorge H. Capdevila, Raymond F. Novak, Deanna Kroetz
-
Publication number: 20130078660Abstract: Methods and compositions for detecting a protein modification in vitro and in vivo are disclosed. In certain embodiments, the protein modification detected is phosphorylation.Type: ApplicationFiled: March 23, 2011Publication date: March 28, 2013Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Lei Wang, Vanessa K. Lacey, Angela R. Parrish
-
Publication number: 20130078645Abstract: The invention relates to a method of diagnosing or monitoring schizophrenia or other psychotic disorder. The biomarkers used are selected from cyclophilin A, cytosalic non-specific dipepditase, Caoctosin-like protein, Glucose-6-phosphate isomerase, uncharacterized protein KIAA0423, myosin 14, myosin 15, nicotinamide phosphoribosyltransferase, pyruvate kinase isozyme R/L, phosphoglyterate mutase 4.Type: ApplicationFiled: January 28, 2011Publication date: March 28, 2013Applicant: PSYNOVA NEUROTECH LTD.Inventors: Sabine Bahn, Marlis Huebner
-
Publication number: 20130078644Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS.Type: ApplicationFiled: November 21, 2012Publication date: March 28, 2013Applicant: DVS SCIENCES, INC.Inventor: DVS SCIENCES, INC.
-
Patent number: 8404453Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.Type: GrantFiled: May 13, 2009Date of Patent: March 26, 2013Assignee: Metheresis Translational Research SAInventors: Cristina Basilico, Paolo Michieli, Paolo Carminati, Paolo Maria Comoglio
-
Publication number: 20130071495Abstract: The present invention relates to an inhibitor of glycogen synthase kinase 3 (GSK-3) for use in a method of treating or preventing emphysema, a method of activating an emphysema cell, an activated emphysema cell obtained by this method for use in a method of treating or preventing emphysema, and a method of screening for a substance for treating or preventing emphysema.Type: ApplicationFiled: March 16, 2011Publication date: March 21, 2013Applicant: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbHInventors: Melanie Koenigshoff, Oliver Eickelberg
-
Publication number: 20130072494Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Inventors: Hing L. SHAM, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gergely Toth
-
Publication number: 20130071389Abstract: The present invention provides methods of treating inflammatory diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits pigment epithelium-derived factor (PEDF) and methods of screening for agents that inhibit PEDF.Type: ApplicationFiled: May 5, 2011Publication date: March 21, 2013Applicant: The Feinstein Institute For Medical ResearchInventors: Kevin Tracey, Sangeeta Chavan
-
Patent number: 8399213Abstract: The invention relates in general to tyrosine dephosphorylation. More specifically, the invention relates to methods and compositions for monitoring intracellular tyrosine dephosphorylation at the single cell level. The invention further relates to techniques that can be used as aid in the development of novel therapeutics, and monitor regulation of intracellular tyrosine phosphatase activity at the single cell level.Type: GrantFiled: September 30, 2009Date of Patent: March 19, 2013Assignee: University of Southern CaliforniaInventors: Nunzio Bottini, Stephanie Stanford, Amy Barrios, Sayantan Mitra
-
Publication number: 20130065262Abstract: A kit for detecting or measuring glycosyltransferase activity including a first reagent comprising a phosphatase and a second reagent comprising a free phosphate detector, and method of detecting and measuring glycosyltransferase activity. A sugar donor, an acceptor substrate, a glycosyltransferase enzyme and a phosphatase are combined and the amount of free phosphate present in the product is measured and used to calculate the activity of the glycosyltransferase enzyme.Type: ApplicationFiled: May 24, 2010Publication date: March 14, 2013Applicant: RESEARCH AND DIAGNOSTIC SYSTEMS, INC.Inventor: Zhenliang L. Wu
-
Publication number: 20130059319Abstract: A method and device are disclosed for continuously detecting, classifying and identifying toxic particles, aerosols and/or vapor in an air sample, in near real time by directing an air sample containing an optional target analyte, in the form of particles, aerosols and/or vapors, enzyme(s), and enzyme substrate(s), to a surface of a collection matrix for forming a biocatalytic reaction product of a plurality of freely mobile optical reporters, and by using a light source with optical reader to interpret the signal from the optical reporter, enabling the detection, classification and identification of toxic particles, aerosols and/or vapor in the air sample.Type: ApplicationFiled: September 2, 2011Publication date: March 7, 2013Inventors: Markus Erbeldinger, David B. Silcott, Jason Aaron Berberich, Keith E. LeJeune
-
Patent number: 8388982Abstract: Compositions, devices, systems and methods for reducing and/or preventing photo-induced damage of one or more reactants in an illuminated analytical reaction by addition of one or more photo-induced damage mitigating agents to the reaction mixture and allowing the reaction to proceed for a period that is less than a photo-induced damage threshold period.Type: GrantFiled: November 19, 2009Date of Patent: March 5, 2013Assignee: Pacific Biosciences of California, Inc.Inventors: Xiangxu Kong, Gene Shen, Andrei Fedorov, John Lyle, Grace Lee, Lubomir Sebo, Duc Do, Robert Weber, Stephen Dudek
-
Publication number: 20130052675Abstract: The present invention relates to a testing system for assessing hypoxia induced cellular damage in a mammal including human, comprising a disposable device having a sample inlet and a collection chamber separated by a separation device wherein the collection chamber is connected to at least two, a first and a second, visible detection compartments, whereof at least one is arranged with chemical means for direct visual detection, said first detection compartment being arranged to determine whether level of hemoglobin (Hb) in a sample of body fluid taken from said mammal exceeds a predetermined threshold value, and said second detection compartment being arranged to evaluate level of total amount of lactate dehydrogenase (LDH) in said sample.Type: ApplicationFiled: September 30, 2010Publication date: February 28, 2013Applicant: CALMARK SWEDEN AKTIEBOLAGInventors: Mathias Karlsson, Sofia Hiort af Ornäs
-
Publication number: 20130053243Abstract: The present invention refers to a method for controlling undesired vegetation at a plant cultivation site. The method comprises the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type hydroxyphenyl pyruvate dioxygenase or a mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD) which is resistant or tolerant to a coumarone-derivative herbicide and/or a nucleotide sequence encoding a wild-type homogentisate solanesyl transferase or a mutated homogentisate solanesyl tranferase (mut-HST) which is resistant or tolerant to a coumarone derivative herbicide, and then applying an effective amount of said herbicide to said plant cultivation site. The invention further refers to plants comprising mut-HPPD and to methods of obtaining such plants.Type: ApplicationFiled: May 2, 2011Publication date: February 28, 2013Applicant: BASF SEInventors: Thomas Mietzner, Matthias Witschel, Johannes Hutzler, Thomas Ehrhardt, Stefan Tresch
-
Patent number: 8383382Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.Type: GrantFiled: September 24, 2010Date of Patent: February 26, 2013Assignee: Codexis, Inc.Inventors: Lynne Gilson, Steven James Collier, Joly Sukumaran, Wan Lin Yeo, Oscar Alvizo, Ee Ling Teo, Robert John Wilson, Junye Xu
-
Patent number: 8383086Abstract: The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or polypeptide in combination with a nicotinamide riboside-related prodrug are also provided. The present invention further provides screening methods for isolating a nicotinamide riboside-related prodrug and identifying a natural source of nicotinamide riboside.Type: GrantFiled: April 12, 2012Date of Patent: February 26, 2013Assignee: Trustees of Dartmouth CollegeInventor: Charles M. Brenner
-
Patent number: 8383425Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.Type: GrantFiled: October 21, 2010Date of Patent: February 26, 2013Assignee: California Institute of TechnologyInventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
-
Publication number: 20130046009Abstract: The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic malignancies.Type: ApplicationFiled: August 15, 2012Publication date: February 21, 2013Inventor: Reuben Kapur
-
Publication number: 20130045498Abstract: The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. 1) equipped with at least one pressure sensor (FIG. 1 (4)) to determine the change in the fluid viscosity over time as a measure of the enzyme activity.Type: ApplicationFiled: March 1, 2011Publication date: February 21, 2013Applicant: NOVOZYMES A/SInventors: Gernot J. Abel, Dan Petterson
-
Publication number: 20130040310Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.Type: ApplicationFiled: December 15, 2010Publication date: February 14, 2013Applicant: Salk Institute for Biological StudiesInventors: Reuben Shaw, Daniel F. Egan, Maria Mihavlova, David Shackelford
-
Publication number: 20130040327Abstract: The present invention is a method for identifying compounds that are allosteric and/or other novel ACAT inhibitors that is based on the novel finding that pregnenolone is a substrate for ACAT; esterification of pregnenolone by ACAT is dramatically activated when cholesterol is present in the assay. The method comprises measuring the esterification of pregnenolone by ACAT under two different conditions: with cholesterol, or without cholesterol. This method can be used to test and categorize various candidate ACAT inhibitors as allosteric or other novel ACAT inhibitors, or it can be used in high-throughput screening for identifying such ACAT inhibitors.Type: ApplicationFiled: May 3, 2011Publication date: February 14, 2013Applicant: TRUSTEES OF DARTMOUTH COLLEGEInventors: Ta-Yuan Chang, Catherine C.Y. Chang
-
Patent number: 8372617Abstract: The present invention provides an extremely useful and novel ?-galactoside-?2,6-sialyltransferase having an optimum reaction pH in a neutral to alkaline range, and a nucleic acid encoding the sialyltransferase. The present invention further provides a vector carrying a nucleic acid encoding the sialyltransferase, and a host cell transformed with the vector, as well as a method for producing a recombinant ?-galactoside-?2,6-sialyltransferase.Type: GrantFiled: April 25, 2012Date of Patent: February 12, 2013Assignee: Japan Tobacco Inc.Inventors: Takeshi Yamamoto, Yoshimitsu Takakura, Toshiki Mine, Yoko Hamada, Hitomi Kajiwara, Masako Ichikawa, Hiroshi Tsukamoto
-
Publication number: 20130034558Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: ApplicationFiled: January 26, 2011Publication date: February 7, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Publication number: 20130035334Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.Type: ApplicationFiled: September 7, 2012Publication date: February 7, 2013Applicant: Pharmacyclics, Inc.Inventors: Lee HONIGBERG, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
-
Patent number: 8367360Abstract: The present invention provides methods of screening for candidate compounds useful in the treatment of Alzheimer's disease and related conditions by inhibiting specific phosphorylation of tau protein by tyrosine kinase c-Abl.Type: GrantFiled: June 21, 2005Date of Patent: February 5, 2013Assignees: Proteome Sciences plc, King's College LondonInventors: Malcolm Ward, Helen Byers, Brian Henry Anderton, Pascal Derkinderen, Christopher Hugh Reynolds, Ritchie Williamson
-
Patent number: 8367361Abstract: A method of using O6-alkylguanine-DNA alkyltransferase (AGT) is disclosed for transferring a label from a substrate to a fusion protein comprising the AGT. This allows the detection and/or manipulating of the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such molecules are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilisation of the fusion protein.Type: GrantFiled: January 24, 2011Date of Patent: February 5, 2013Assignee: Ecole Polytechnique Federale de LausanneInventors: Kai Johnsson, Susanne Kindermann (née Gendreizig), Antje Keppler
-
Publication number: 20130029878Abstract: Provided are a method for measuring histone methyltransferase activity, a method for screening for compounds that inhibit histone methyltransferase activity, a reagent kit for measuring histone methyltransferase activity, and a kit for screening for compounds that inhibit histone methyltransferase activity. A substrate compound represented by general formula (I): R1—X—K—R2 (I), or a salt thereof, wherein R1 represents a hydrogen atom or a protecting group for an amino terminus; X represents a peptide consisting of 0 or 1 or more amino acid residues; K represents a lysine residue; and R2 represents a dye label linked via an amide bond to the carbonyl terminus of a lysine residue, wherein the cleavage of the amide bond by peptidase changes the fluorescence property or chromogenic property of the dye label, and the methylation of the ? amino group of the lysine residue by the histone methyltransferase decreases susceptibility to peptidase, is used.Type: ApplicationFiled: April 15, 2011Publication date: January 31, 2013Applicant: KYUSHU INSTITUTE OF TECHNOLOGYInventors: Norikazu Nishino, Yasushi Takemoto, Akihiro Ito, Minoru Yoshida
-
Publication number: 20130029324Abstract: The present invention provides methods to concentrate cells onto microparticles, to concentrate the microparticles, and to detect the cells. The present invention also includes unitary sample preparation and detection devices to be used in accordance with the methods.Type: ApplicationFiled: December 30, 2010Publication date: January 31, 2013Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Raj Rajagopal, Kurt J. Halverson, Manjiri T. Kshirsagar, James E. Aysta
-
Publication number: 20130028856Abstract: Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.Type: ApplicationFiled: February 22, 2012Publication date: January 31, 2013Inventors: Gregory I. Frost, Ping Jiang, Curtis B. Thompson
-
Patent number: 8362227Abstract: The invention provides methods to detect C. difficile in biological samples using real-time PCR. Primers and probes for the detection of C. difficile are provided by the invention. Articles of manufacture containing such primers and probes for detecting C. difficile are further provided by the invention.Type: GrantFiled: January 9, 2012Date of Patent: January 29, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventors: Franklin R. Cockerill, III, Thomas F. Smith, Jon E. Rosenblatt, Lynne M. Sloan
-
Publication number: 20130022999Abstract: The present invention describes a method for detecting biomolecular interactions said method comprising: (a) selecting an appropriate reporter molecule selected from the group consisting of a protein, a fluorescent protein, a luminescent protein and a phosphorescent protein; (b) effecting fragmentation of said reporter molecule such that said fragmentation results in reversible loss of reporter function; (c) fusing or attaching fragments of said reporter molecule separately to other molecules; followed by (d) reassociation of said reporter fragments through interactions of the molecules that are fused to said fragments; and (e) detecting said biomolecular interactions by reconstitution of activity of the reporter moleculeType: ApplicationFiled: June 4, 2012Publication date: January 24, 2013Applicant: Odyssey Pharmaceuticals, Inc.Inventors: Stephen William Watson Michnick, Joelle Nina Polletier, Ingrid Remy
-
Publication number: 20130023565Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase possessing endonuclease activity, wherein said PA subunit is from Influenza A 2009 pan-demic H1N1 virus or is a variant thereof. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.Type: ApplicationFiled: March 15, 2011Publication date: January 24, 2013Applicant: European Molecular Biology LaboratoryInventors: Stephen Cusack, Eva Kowalinski, Chloe Zubieta
-
Publication number: 20130017550Abstract: Methods for identifying a therapeutic agent for treating a Germinal Center Kinase (GCK)-Like Kinase (GLK)-mediated disease are disclosed. Methods for detecting a modulation of GLK signaling by a lest compound are disclosed. Also disclosed are methods for detecting the presence and/or severity of an autoimmune disease and/or cancer.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Tse-Hua TAN, Huai-Chia Chuang
-
Publication number: 20130017548Abstract: The present invention relates to a novel method for screening for a therapeutic or prophylactic agent for an inflammatory disease. More particularly, the present invention relates to a method for screening for a therapeutic or prophylactic agent for an inflammatory disease by selecting a substance having an inhibitory activity specific to PIKfyve by using the presence or absence of the inhibitory activity as an indicator.Type: ApplicationFiled: June 27, 2012Publication date: January 17, 2013Applicant: AJINOMOTO, INC.Inventors: Sen Takeshita, Takashi Yamamoto, Ayatoshi Andou, Tomohisa Okutsu, Agung Eviryanti, Naoyuki Fukuchi, Shunsuke Kageyama
-
Patent number: 8354244Abstract: The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/L or greater.Type: GrantFiled: December 12, 2011Date of Patent: January 15, 2013Inventors: Randy Ringold, Renee Parker, Douglas H Thamm
-
Publication number: 20130011870Abstract: A method for diagnosing a disease or for evaluating the risk to develop a disease which is characterized by dyslipidemia in humans, in particular for diagnosing atherosclerosis, coronary heart disease, peripheral vascular disease, stroke, metabolic syndrome, diabetes (type I and II) and diabetes related sequale (diabetic polyneuropathy, diabetic retinopathie or diabetic nephropathie) as well as lipid associated neuropathies (like Charcot-Marie-Tooth neuropathies such as hereditary sensory and autonomous neuropathy type 1 (HSAN1)) by measurement of atypical products of serine palmitoyltransferase.Type: ApplicationFiled: July 19, 2012Publication date: January 10, 2013Inventor: Thorsten Hornemann
-
Patent number: 8349576Abstract: Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein.Type: GrantFiled: July 15, 2010Date of Patent: January 8, 2013Assignee: University of Medicine and Dentistry of New JerseyInventors: Alexey G. Ryazanov, Benjamin E. Turk